-
Body mass index, waist circumference, and mortality in subjects older than 80 years: a Mendelian randomization study Eur. Heart J. (IF 39.3) Pub Date : 2024-04-16 Yuebin Lv, Yue Zhang, Xinwei Li, Xiang Gao, Yongyong Ren, Luojia Deng, Lanjing Xu, Jinhui Zhou, Bing Wu, Yuan Wei, Xingyao Cui, Zinan Xu, Yanbo Guo, Yidan Qiu, Lihong Ye, Chen Chen, Jun Wang, Chenfeng Li, Yufei Luo, Zhaoxue Yin, Chen Mao, Qiong Yu, Hui Lu, Virginia Byers Kraus, Yi Zeng, Shilu Tong, Xiaoming Shi
Background and Aims Emerging evidence has raised an obesity paradox in observational studies of body mass index (BMI) and health among the oldest-old (aged ≥80 years), as an inverse relationship of BMI with mortality was reported. This study was to investigate the causal associations of BMI, waist circumference (WC), or both with mortality in the oldest-old people in China. Methods A total of 5306
-
Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study Eur. Heart J. (IF 39.3) Pub Date : 2024-04-15 Qingui Chen, Nienke van Rein, Tom van der Hulle, Julius C Heemelaar, Serge A Trines, Henri H Versteeg, Frederikus A Klok, Suzanne C Cannegieter
Background and Aims Coexisting atrial fibrillation (AF) and cancer challenge the management of both. The aim of the study is to comprehensively provide the epidemiology of coexisting AF and cancer. Methods Using Dutch nationwide statistics, individuals with incident AF (n = 320 139) or cancer (n = 472 745) were identified during the period 2015–19. Dutch inhabitants without a history of AF (n = 320
-
Ischaemic stroke in women with atrial fibrillation: temporal trends and clinical implications Eur. Heart J. (IF 39.3) Pub Date : 2024-04-12 Konsta Teppo, K E Juhani Airaksinen, Jussi Jaakkola, Olli Halminen, Birgitta Salmela, Elis Kouki, Jari Haukka, Jukka Putaala, Miika Linna, Aapo L Aro, Pirjo Mustonen, Juha Hartikainen, Gregory Y H Lip, Mika Lehto
Background and Aims Female sex has been linked with higher risk of ischaemic stroke (IS) in atrial fibrillation (AF), but no prior study has examined temporal trends in the IS risk associated with female sex. Methods The registry-linkage Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study included all patients with AF in Finland from 2007 to 2018. Ischaemic stroke rates and rate ratios were
-
Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α Eur. Heart J. (IF 39.3) Pub Date : 2024-04-12 Xingliang Zhou, Yiwei Liu, Yi Shen, Lijun Chen, Wenting Hu, Yi Yan, Bei Feng, Li Xiang, Yifan Zhu, Chenyu Jiang, Zihao Dai, Xu Huang, Liwei Wu, Tianyu Liu, Lijun Fu, Caiwen Duan, Shuhong Shen, Jun Li, Hao Zhang
Background and Aims Patients with acute myeloid leukaemia (AML) suffer from severe myocardial injury during daunorubicin (DNR)-based chemotherapy and are at high risk of cardiac mortality. The crosstalk between tumour cells and cardiomyocytes might play an important role in chemotherapy-related cardiotoxicity, but this has yet to be demonstrated. This study aimed to identify its underlying mechanism
-
Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality Eur. Heart J. (IF 39.3) Pub Date : 2024-04-09 Christian Paludan-Müller, Oliver B Vad, Niels K Stampe, Søren Z Diederichsen, Laura Andreasen, Laia M Monfort, Emil L Fosbøl, Lars Køber, Christian Torp-Pedersen, Jesper H Svendsen, Morten S Olesen
Background and Aims Patients with atrial fibrillation (AF) are at increased risks of cardiovascular diseases and mortality, but risks according to age at diagnosis have not been reported. This study investigated age-specific risks of outcomes among patients with AF and the background population. Methods This nationwide population-based cohort study included patients with AF and controls without outcomes
-
Use of new and emerging cancer drugs: what the cardiologist needs to know Eur. Heart J. (IF 39.3) Pub Date : 2024-04-09 Iacopo Fabiani, Michela Chianca, Alberto Aimo, Michele Emdin, Susan Dent, Antonella Fedele, Carlo Maria Cipolla, Daniela Maria Cardinale
The last decade has witnessed a paradigm shift in cancer therapy, from non-specific cytotoxic chemotherapies to agents targeting specific molecular mechanisms. Nonetheless, cardiovascular toxicity of cancer therapies remains an important concern. This is particularly relevant given the significant improvement in survival of solid and haematological cancers achieved in the last decades. Cardio-oncology
-
Catheter-based therapy for high-risk or intermediate-risk pulmonary embolism: death and re-hospitalization Eur. Heart J. (IF 39.3) Pub Date : 2024-04-04 Orly Leiva, Carlos Alviar, Sameer Khandhar, Sahil A Parikh, Catalin Toma, Radu Postelnicu, James Horowitz, Vikramjit Mukherjee, Allison Greco, Sripal Bangalore
Background and Aims Catheter-based therapies (CBTs) have been developed as a treatment option in patients with pulmonary embolism (PE). There remains a paucity of data to inform decision-making in patients with intermediate-risk or high-risk PE. The aim of this study was to characterize in-hospital and readmission outcomes in patients with intermediate-risk or high-risk PE treated with vs. without
-
Syphilis and cardiovascular risk: a Taiwanese registry Eur. Heart J. (IF 39.3) Pub Date : 2024-04-03 Victor Chien-Chia Wu, Jih-Kai Yeh, Shao-Wei Chen, Chia-Ling Wu, Yu-Sheng Lin, Michael Wu, Kai-Che Wei, Pao-Hsien Chu, Shang-Hung Chang, Yu-Tung Huang
Background and Aims Studies on the impact of syphilis on the cardiovascular system in large populations are limited. This study investigated the effects of syphilis on cardiovascular outcomes. Methods Medical records from 2010 to 2015 were retrieved from the Taiwan National Health Insurance Research Database, linked to the Notifiable Infectious Diseases database from the Taiwan Centers for Disease
-
Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease Eur. Heart J. (IF 39.3) Pub Date : 2024-03-29 Ling Li, Shichao Pang, Fabian Starnecker, Bertram Mueller-Myhsok, Heribert Schunkert
Background and Aims It is not clear how a polygenic risk score (PRS) can be best combined with guideline-recommended tools for cardiovascular disease (CVD) risk prediction, e.g. SCORE2. Methods A PRS for coronary artery disease (CAD) was calculated in participants of UK Biobank (n = 432 981). Within each tenth of the PRS distribution, the odds ratios (ORs)—referred to as PRS-factor—for CVD (i.e. CAD
-
Patient–physician sex concordance and outcomes in cardiovascular disease: a systematic review Eur. Heart J. (IF 39.3) Pub Date : 2024-03-29 Lamia Harik, Ko Yamamoto, Takeshi Kimura, Lisa Q Rong, Birgit Vogel, Roxana Mehran, C Noel Bairey-Merz, Mario Gaudino
The sex disparity in outcomes of patients with cardiovascular disease is well-described and has persisted across recent decades. While there have been several proposed mechanisms to explain this disparity, there are limited data on female patient–physician sex concordance and its association with outcomes. The authors review the existing literature on the relationship between patient–physician sex
-
Artificial intelligence–based assessment of built environment from Google Street View and coronary artery disease prevalence Eur. Heart J. (IF 39.3) Pub Date : 2024-03-28 Zhuo Chen, Jean-Eudes Dazard, Yassin Khalifa, Issam Motairek, Sadeer Al-Kindi, Sanjay Rajagopalan
Background and Aims Built environment plays an important role in the development of cardiovascular disease. Tools to evaluate the built environment using machine vision and informatic approaches have been limited. This study aimed to investigate the association between machine vision–based built environment and prevalence of cardiometabolic disease in US cities. Methods This cross-sectional study used
-
Cardiac implantable electronic devices and bloodstream infections: management and outcomes Eur. Heart J. (IF 39.3) Pub Date : 2024-03-28 Tardu Özkartal, Andrea Demarchi, Giulio Conte, Damiano Pongan, Catherine Klersy, Maria Luce Caputo, Marco Bergonti, Enos Bernasconi, Valeria Gaia, Christopher B Granger, Angelo Auricchio
Background and Aims Bloodstream infection (BSI) of any cause may lead to device infection in cardiac implantable electronic device (CIED) patients. Aiming for a better understanding of the diagnostic approach, treatment, and outcome, patients with an implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy and defibrillator (CRT-D) hospitalized with BSI were investigated.
-
Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial Eur. Heart J. (IF 39.3) Pub Date : 2024-03-21 Daniel A Jones, Anne-Marie Beirne, Matthew Kelham, Lucinda Wynne, Mervyn Andiapen, Krishnaraj S Rathod, Tipparat Parakaw, Jessica Adams, Annastazia Learoyd, Kamran Khan, Thomas Godec, Paul Wright, Sotiris Antoniou, Andrew Wragg, Muhammad Yaqoob, Anthony Mathur, Amrita Ahluwalia
Background and Aims Contrast-induced nephropathy (CIN), also known as contrast-associated acute kidney injury (CA-AKI) underlies a significant proportion of the morbidity and mortality following coronary angiographic procedures in high-risk patients and remains a significant unmet need. In pre-clinical studies inorganic nitrate, which is chemically reduced in vivo to nitric oxide, is renoprotective
-
Anderson–Fabry disease management: role of the cardiologist Eur. Heart J. (IF 39.3) Pub Date : 2024-03-15 Maurizio Pieroni, Mehdi Namdar, Iacopo Olivotto, Robert J Desnick
Anderson–Fabry disease (AFD) is a lysosomal storage disorder characterized by glycolipid accumulation in cardiac cells, associated with a peculiar form of hypertrophic cardiomyopathy (HCM). Up to 1% of patients with a diagnosis of HCM indeed have AFD. With the availability of targeted therapies for sarcomeric HCM and its genocopies, a timely differential diagnosis is essential. Specifically, the therapeutic
-
Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction Eur. Heart J. (IF 39.3) Pub Date : 2024-03-15 Gemma Vilahur, Monika Radike, Pablo Sutelman, Soumaya Ben-Aicha, Manuel Gutiérrez, Laura Casaní, Daniel Hovdal, Emily L Ongstad, Anders Gabrielsen, Alberto Hidalgo, Ola Fjellström, Leif Carlsson, Lina Badimon
Background and Aims The ecto–nucleoside triphosphate diphosphohydrolases of the CD39 family degrade ATP and ADP into AMP, which is converted into adenosine by the extracellular CD73/ecto-5-nucleotidase. This pathway has been explored in antithrombotic treatments but little in myocardial protection. We have investigated whether the administration of solCD39L3 (AZD3366) confers additional cardioprotection
-
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence Eur. Heart J. (IF 39.3) Pub Date : 2024-03-05 Nabil V Sayour, Ágnes M Paál, Pietro Ameri, Wouter C Meijers, Giorgio Minotti, Ioanna Andreadou, Antonella Lombardo, Massimiliano Camilli, Heinz Drexel, Erik Lerkevang Grove, Gheorghe Andrei Dan, Andreea Ivanescu, Anne Grete Semb, Gianluigi Savarese, Dobromir Dobrev, Filippo Crea, Juan-Carlos Kaski, Rudolf A de Boer, Péter Ferdinandy, Zoltán V Varga
Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy
-
Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment Eur. Heart J. (IF 39.3) Pub Date : 2024-03-05 Denisa Muraru, Luigi P Badano, Rebecca T Hahn, Roberto M Lang, Victoria Delgado, Nina C Wunderlich, Erwan Donal, Maurizio Taramasso, Alison Duncan, Philipp Lurz, Tom De Potter, José L Zamorano Gómez, Jeroen J Bax, Ralph Stephan von Bardeleben, Maurice Enriquez-Sarano, Francesco Maisano, Fabien Praz, Marta Sitges
Atrial secondary tricuspid regurgitation (A-STR) is a distinct phenotype of secondary tricuspid regurgitation with predominant dilation of the right atrium and normal right and left ventricular function. Atrial secondary tricuspid regurgitation occurs most commonly in elderly women with atrial fibrillation and in heart failure with preserved ejection fraction in sinus rhythm. In A-STR, the main mechanism
-
Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry Eur. Heart J. (IF 39.3) Pub Date : 2024-03-01 Mikhael F El-Chami, Christophe Garweg, Nicolas Clementy, Faisal Al-Samadi, Saverio Iacopino, Jose Luis Martinez-Sande, Paul R Roberts, Claudio Tondo, Jens Brock Johansen, Xavier Vinolas-Prat, Yong-Mei Cha, Eric Grubman, Pierre Bordachar, Kurt Stromberg, Dedra H Fagan, Jonathan P Piccini
Background and Aims Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Micra VR leadless pacemaker through five years from the worldwide post-approval registry (PAR) was assessed. Methods All Micra PAR patients undergoing
-
Transcatheter treatment of the tricuspid valve: current status and perspectives Eur. Heart J. (IF 39.3) Pub Date : 2024-03-01 Francesco Maisano, Rebecca Hahn, Paul Sorajja, Fabien Praz, Philipp Lurz
Transcatheter tricuspid valve interventions (TTVI) are emerging as alternatives to surgery in high-risk patients with isolated or concomitant tricuspid regurgitation. The development of new minimally invasive solutions potentially more adapted to this largely undertreated population of patients, has fuelled the interest for the tricuspid valve. Growing evidence and new concepts have contributed to
-
Kidney replacement therapy: trends in incidence, treatment, and outcomes of myocardial infarction and stroke in a nationwide Scottish study Eur. Heart J. (IF 39.3) Pub Date : 2024-03-01 Peter J Gallacher, David Yeung, Samira Bell, Anoop S V Shah, Nicholas L Mills, Neeraj Dhaun
Background and Aims Patients with kidney failure have a higher risk of cardiovascular disease compared with the general population. Whilst temporal trends of myocardial infarction and stroke are declining in the general population, these have not been evaluated in patients with kidney failure. This study aimed to describe national trends in the incidence, treatment, and outcomes of myocardial infarction
-
Rheumatoid arthritis and cardiovascular complications during delivery: a United States inpatient analysis Eur. Heart J. (IF 39.3) Pub Date : 2024-03-01 Salman Zahid, Mohamed S Mohamed, Aardra Rajendran, Anum S Minhas, Muhammad Zia Khan, Noreen T Nazir, Anthony J Ocon, Brittany N Weber, Ijeoma Isiadinso, Erin D Michos
Background and Aims Persons with rheumatoid arthritis (RA) have an increased risk of obstetric-associated complications, as well as long-term cardiovascular (CV) risk. Hence, the aim was to evaluate the association of RA with acute CV complications during delivery admissions. Methods Data from the National Inpatient Sample (2004–2019) were queried utilizing ICD-9 or ICD-10 codes to identify delivery
-
Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study Eur. Heart J. (IF 39.3) Pub Date : 2024-03-01 Kamel Mohammedi, Marie Pigeyre, Jackie Bosch, Salim Yusuf, Hertzel C Gerstein
Background and Aims Few studies have compared arm and ankle blood pressures (BPs) with regard to peripheral artery disease (PAD) and mortality. These relationships were assessed using data from three large prospective clinical trials. Methods Baseline BP indices included arm systolic BP (SBP), diastolic BP (DBP), pulse pressure (arm SBP minus DBP), ankle SBP, ankle–brachial index (ABI, ankle SBP divided
-
Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis Eur. Heart J. (IF 39.3) Pub Date : 2024-02-28 Jude Moutchia, Robyn L McClelland, Nadine Al-Naamani, Dina H Appleby, John H Holmes, Jasleen Minhas, Jeremy A Mazurek, Harold I Palevsky, Corey E Ventetuolo, Steven M Kawut
Background and Aims Effective therapies that target three main signalling pathways are approved to treat pulmonary arterial hypertension (PAH). However, there are few large patient-level studies that compare the effectiveness of these pathways. The aim of this analysis was to compare the effectiveness of the treatment pathways in PAH and to assess treatment heterogeneity. Methods A network meta-analysis
-
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial Eur. Heart J. (IF 39.3) Pub Date : 2024-02-22 Giovanna Petrucci, Georgina A Buck, Bianca Rocca, Sarah Parish, Colin Baigent, Duaa Hatem, Marion Mafham, Aida Habib, Louise Bowman, Jane Armitage, Carlo Patrono
Background and Aims Thromboxane (TX) A2, released by activated platelets, plays an important role in atherothrombosis. Urinary 11-dehydro-TXB2 (U-TXM), a stable metabolite reflecting the whole-body TXA2 biosynthesis, is reduced by ∼70% by daily low-dose aspirin. The U-TXM represents a non-invasive biomarker of in vivo platelet activation and is enhanced in patients with diabetes. This study assessed
-
Device innovation in cardiovascular medicine: a report from the European Society of Cardiology Cardiovascular Round Table Eur. Heart J. (IF 39.3) Pub Date : 2024-02-17 Stephan Windecker, Martine Gilard, Stephan Achenbach, Alain Cribier, Victoria Delgado, Nataliya Deych, Inga Drossart, Hélène Eltchaninoff, Alan G Fraser, Alexandra Goncalves, Gerhard Hindricks, Richard Holborow, Arie Pieter Kappetein, John Kilmartin, Jana Kurucova, Thomas F Lüscher, Roxana Mehran, Donal B O’Connor, Mark Perkins, Eigil Samset, Ralph Stephan von Bardeleben, Franz Weidinger
Research performed in Europe has driven cardiovascular device innovation. This includes, but is not limited to, percutaneous coronary intervention, cardiac imaging, transcatheter heart valve implantation, and device therapy of cardiac arrhythmias and heart failure. An important part of future medical progress involves the evolution of medical technology and the ongoing development of artificial intelligence
-
Ischaemic heart disease in patients with cancer Eur. Heart J. (IF 39.3) Pub Date : 2024-02-07 Pietro Ameri, Edoardo Bertero, Marco Lombardi, Italo Porto, Marco Canepa, Anju Nohria, Rocco Vergallo, Alexander R Lyon, Teresa López-Fernández
Cardiologists are encountering a growing number of cancer patients with ischaemic heart disease (IHD). Several factors account for the interrelationship between these two conditions, in addition to improving survival rates in the cancer population. Established cardiovascular (CV) risk factors, such as hypercholesterolaemia and obesity, predispose to both IHD and cancer, through specific mechanisms
-
Human papillomavirus infection and cardiovascular mortality: a cohort study Eur. Heart J. (IF 39.3) Pub Date : 2024-02-07 Hae Suk Cheong, Yoosoo Chang, Yejin Kim, Min-Jung Kwon, Yoosun Cho, Bomi Kim, Eun-Jeong Joo, Young Ho Bae, Chanmin Kim, Seungho Ryu
Background and Aims High-risk human papillomavirus (HR-HPV) infection—a well-established risk factor for cervical cancer—has associations with cardiovascular disease (CVD). However, its relationship with CVD mortality remains uncertain. This study examined the associations between HR-HPV infection and CVD mortality. Methods As part of a health examination, 163 250 CVD-free Korean women (mean age: 40
-
Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial Eur. Heart J. (IF 39.3) Pub Date : 2024-02-07 Hans Gustav Hørsted Thyregod, Troels Højsgaard Jørgensen, Nikolaj Ihlemann, Daniel Andreas Steinbrüchel, Henrik Nissen, Bo Juel Kjeldsen, Petur Petursson, Ole De Backer, Peter Skov Olsen, Lars Søndergaard
Background and Aims Transcatheter aortic valve implantation (TAVI) has become a viable treatment option for patients with severe aortic valve stenosis across a broad range of surgical risk. The Nordic Aortic Valve Intervention (NOTION) trial was the first to randomize patients at lower surgical risk to TAVI or surgical aortic valve replacement (SAVR). The aim of the present study was to report clinical
-
Impact of untreated chronic obstructive coronary artery disease on outcomes after transcatheter aortic valve replacement Eur. Heart J. (IF 39.3) Pub Date : 2024-01-25 Ian Persits, Habib Layoun, Nicholas P Kondoleon, Nikolaos Spilias, Osamah Badwan, Joseph Sipko, James J Yun, Ankur Kalra, Iryna Dykun, Larisa G Tereshchenko, Amar Krishnaswamy, Grant W Reed, Samir R Kapadia, Rishi Puri
Background and Aims In transcatheter aortic valve replacement (TAVR) recipients, the optimal management of concomitant chronic obstructive coronary artery disease (CAD) remains unknown. Some advocate for pre-TAVR percutaneous coronary intervention, while others manage it expectantly. The aim of this study was to assess the impact of varying degrees and extent of untreated chronic obstructive CAD on
-
Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk Eur. Heart J. (IF 39.3) Pub Date : 2024-01-20 Émilie Gobeil, Jérôme Bourgault, Patricia L Mitchell, Ursula Houessou, Eloi Gagnon, Arnaud Girard, Audrey Paulin, Hasanga D Manikpurage, Valérie Côté, Christian Couture, Simon Marceau, Yohan Bossé, Sébastien Thériault, Patrick Mathieu, Marie-Claude Vohl, André Tchernof, Benoit J Arsenault
Background and Aims RNA-based, antibody-based, and genome editing-based therapies are currently under investigation to determine if the inhibition of angiopoietin-like protein-3 (ANGPTL3) could reduce lipoprotein-lipid levels and atherosclerotic cardiovascular disease (ASCVD) risk. Mendelian randomisation (MR) was used to determine whether genetic variations influencing ANGPTL3 liver gene expression
-
Cardiovascular disease risk communication and prevention: a meta-analysis Eur. Heart J. (IF 39.3) Pub Date : 2024-01-20 Mina Bakhit, Samantha Fien, Eman Abukmail, Mark Jones, Justin Clark, Anna Mae Scott, Paul Glasziou, Magnolia Cardona
Background and Aims Knowledge of quantifiable cardiovascular disease (CVD) risk may improve health outcomes and trigger behavioural change in patients or clinicians. This review aimed to investigate the impact of CVD risk communication on patient-perceived CVD risk and changes in CVD risk factors. Methods PubMed, Embase, and PsycINFO databases were searched from inception to 6 June 2023, supplemented
-
Changes in frailty and incident cardiovascular disease in three prospective cohorts Eur. Heart J. (IF 39.3) Pub Date : 2024-01-19 Di He, Zhaoping Wang, Jun Li, Kaixin Yu, Yusa He, Xinyue He, Yuanjiao Liu, Yuhao Li, Ruiyi Fu, Dan Zhou, Yimin Zhu
Background and Aims Previous studies found that frailty was an important risk factor for cardiovascular disease (CVD). However, previous studies only focused on baseline frailty status, not taking into consideration the changes in frailty status during follow-up. The aim of this study was to investigate the associations of changes in frailty status with incident CVD. Methods This study used data of
-
C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project Eur. Heart J. (IF 39.3) Pub Date : 2024-01-19 Natalie Arnold, Christopher Blaum, Alina Goßling, Fabian J Brunner, Benjamin Bay, Marco M Ferrario, Paolo Brambilla, Giancarlo Cesana, Valerio Leoni, Luigi Palmieri, Chiara Donfrancesco, Teresa Padró, Jonas Andersson, Pekka Jousilahti, Francisco Ojeda, Tanja Zeller, Allan Linneberg, Stefan Söderberg, Licia Iacoviello, Francesco Gianfagna, Susana Sans, Giovanni Veronesi, Barbara Thorand, Annette Peters
Background and Aims Recent investigations have suggested an interdependence of lipoprotein(a) [Lp(a)]-related risk for cardiovascular disease with background inflammatory burden. The aim the present analysis was to investigate whether high-sensitive C-reactive protein (hsCRP) modulates the association between Lp(a) and coronary heart disease (CHD) in the general population. Methods Data from 71 678
-
Air pollutants, genetic susceptibility, and abdominal aortic aneurysm risk: a prospective study Eur. Heart J. (IF 39.3) Pub Date : 2024-01-19 Yudiyang Ma, Dankang Li, Feipeng Cui, Jianing Wang, Linxi Tang, Yingping Yang, Run Liu, Yaohua Tian
Background and Aims Air pollutants are important contributors to cardiovascular diseases, but associations between long-term exposure to air pollutants and the risk of abdominal aortic aneurysm (AAA) are still unknown. Methods This study was conducted using a sample of 449 463 participants from the UK Biobank. Hazard ratios and 95% confidence intervals for the risk of AAA incidence associated with
-
Mitral transcatheter edge to edge repair versus isolated mitral surgery for severe mitral regurgitation: A French nationwide study Eur. Heart J. (IF 39.3) Pub Date : 2024-01-17 Pierre Deharo, Jean Francois Obadia, Patrice Guerin, Thomas Cuisset, Jean Francois Avierinos, Gilbert Habib, Olivier Torras, Arnaud Bisson, Pascal Vigny, Christophe Saint Etienne, Carl Semaan, Mickael Guglieri, Nicolas Dumonteil, Frederic Collart, Martine Gilard, Thomas Modine, Erwan Donal, Bernard Iung, Laurent Fauchier
Background and Aims Mitral valve surgery and more recently mitral transcatheter edge-to-edge repair (TEER) are the two treatments of severe mitral regurgitation in eligible patients. Clinical comparison of both therapies remains limited by the number of patients analysed. The objective of this study was to analyse the outcomes of mitral TEER versus isolated mitral valve surgery at a nationwide level
-
Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study Eur. Heart J. (IF 39.3) Pub Date : 2024-01-17 Hyo-Jeong Ahn, Hong Yul An, Gangpyo Ryu, Jiwoo Lim, Choonghyun Sun, Han Song, Su-Yeon Choi, Heesun Lee, Taylor Maurer, Daniel Nachun, Soonil Kwon, So-Ryoung Lee, Gregory Y H Lip, Seil Oh, Siddhartha Jaiswal, Youngil Koh, Eue-Keun Choi
Background and Aims Both clonal haematopoiesis of indeterminate potential (CHIP) and atrial fibrillation (AF) are age-related conditions. This study investigated the potential role of CHIP in the development and progression of AF. Methods Deep-targeted sequencing of 24 CHIP mutations (a mean depth of coverage = 1000×) was performed in 1004 patients with AF and 3341 non-AF healthy subjects. Variant
-
Cannabis for chronic pain: cardiovascular safety in a nationwide Danish study Eur. Heart J. (IF 39.3) Pub Date : 2024-01-11 Anders Holt, Nina Nouhravesh, Jarl E Strange, Sebastian Kinnberg Nielsen, Anne-Marie Schjerning, Peter Vibe Rasmussen, Christian Torp-Pedersen, Gunnar H Gislason, Morten Schou, Patricia McGettigan, Morten Lamberts
Background and Aims A rising number of countries allow physicians to treat chronic pain with medical cannabis. However, recreational cannabis use has been linked with cardiovascular side effects, necessitating investigations concerning the safety of prescribed medical cannabis. Methods Using nationwide Danish registers, patients with chronic pain initiating first-time treatment with medical cannabis
-
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials Eur. Heart J. (IF 39.3) Pub Date : 2024-01-10 Alireza Oraii, Jeff S Healey, Krzysztof Kowalik, Avinash K Pandey, Alexander P Benz, Jorge A Wong, David Conen, William F McIntyre
Background and Aims Mineralocorticoid receptor antagonists (MRAs) improve cardiovascular outcomes in a variety of settings. This study aimed to assess whether cardioprotective effects of MRAs are modified by heart failure (HF) and atrial fibrillation (AF) status and to study their impact on AF events. Methods MEDLINE, Embase, and Cochrane Central databases were searched to 24 March 2023 for randomized
-
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe Eur. Heart J. (IF 39.3) Pub Date : 2024-01-10 Richard T Carrick, Corrado De Marco, Alessio Gasperetti, Laurens P Bosman, Jean-Baptiste Gourraud, Alessandro Trancuccio, Andrea Mazzanti, Brittney Murray, Catherine Pendleton, Crystal Tichnell, Harikrishna Tandri, Katja Zeppenfeld, Arthur A M Wilde, Brianna Davies, Colette Seifer, Jason D Roberts, Jeff S Healey, Ciorsti MacIntyre, Wael Alqarawi, Rafik Tadros, Michael J Cutler, Mattia Targetti, Leonardo
Background and Aims Implantable cardioverter-defibrillators (ICDs) are critical for preventing sudden cardiac death (SCD) in arrhythmogenic right ventricular cardiomyopathy (ARVC). This study aims to identify cross-continental differences in utilization of primary prevention ICDs and survival free from sustained ventricular arrhythmia (VA) in ARVC. Methods This was a retrospective analysis of ARVC
-
Severe aortic stenosis: secular trends of incidence and outcomes Eur. Heart J. (IF 39.3) Pub Date : 2024-01-08 Giovanni Benfari, Benjamin Essayagh, Hector I Michelena, Zi Ye, Jose Medina Inojosa, Flavio L Ribichini, Juan Crestanello, David Messika-Zeitoun, Bernard Prendergast, Benjamin F Wong, Prabin Thapa, Maurice Enriquez-Sarano
Background and Aims Severe aortic stenosis (AS) is the guideline-based indication for aortic valve replacement (AVR), which has markedly increased with transcatheter approaches, suggesting possible increasing AS incidence. However, reported secular trends of AS incidence remain contradictory and lack quantitative Doppler echocardiographic ascertainment. Methods All adults residents in Olmsted County
-
Inhibition of a novel Dickkopf-1-LDL receptor–related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice Eur. Heart J. (IF 39.3) Pub Date : 2023-12-28 En Ma, Da Wo, Jinxiao Chen, Hongwei Yan, Xiaohui Zhou, Jia He, Celiang Wu, Qing Wang, Changjing Zuo, Xiao Li, Li Li, Qingshu Meng, Liang Zheng, Luying Peng, Lidian Chen, Jun Peng, Dan-ni Ren, Weidong Zhu
Background and Aims Anti-hypertensive agents are one of the most frequently used drugs worldwide. However, no blood pressure–lowering strategy is superior to placebo with respect to survival in diabetic hypertensive patients. Previous findings show that Wnt co-receptors LDL receptor–related proteins 5 and 6 (LRP5/6) can directly bind to several G protein–coupled receptors (GPCRs). Because angiotensin
-
Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks Eur. Heart J. (IF 39.3) Pub Date : 2023-12-20 Koshiro Kanaoka, Taku Nishida, Yoshitaka Iwanaga, Michikazu Nakai, Reina Tonegawa-Kuji, Yuichi Nishioka, Tomoya Myojin, Katsuki Okada, Tatsuya Noda, Kengo Kusano, Yoshihiro Miyamoto, Yoshihiko Saito, Tomoaki Imamura
Background and Aims Few recent large-scale studies have evaluated the risks and benefits of continuing oral anticoagulant (OAC) therapy after catheter ablation (CA) for atrial fibrillation (AF). This study evaluated the status of continuation of OAC therapy and the association between continuation of OAC therapy and thromboembolic and bleeding events according to the CHADS2 score. Methods This retrospective
-
Tricuspid valve disease and cardiac implantable electronic devices Eur. Heart J. (IF 39.3) Pub Date : 2023-12-14 Martin Andreas, Haran Burri, Fabien Praz, Osama Soliman, Luigi Badano, Manuel Barreiro, João L Cavalcante, Tom de Potter, Torsten Doenst, Kai Friedrichs, Jörg Hausleiter, Nicole Karam, Susheel Kodali, Azeem Latib, Eloi Marijon, Suneet Mittal, Georg Nickenig, Aldo Rinaldi, Piotr Rudzinski, Marco Russo, Christoph Starck, Ralph Stephan von Bardeleben, Nina Wunderlich, José Luis Zamorano, Rebecca T Hahn
The role of cardiac implantable electronic device (CIED)-related tricuspid regurgitation (TR) is increasingly recognized as an independent clinical entity. Hence, interventional TR treatment options continuously evolve, surgical risk assessment and peri-operative care improve the management of CIED-related TR, and the role of lead extraction is of high interest. Furthermore, novel surgical and interventional
-
Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis Eur. Heart J. (IF 39.3) Pub Date : 2023-12-12 Zheng Dong, Lei Hou, Wei Luo, Li-Hong Pan, Xiao Li, Hai-Peng Tan, Run-Da Wu, Hao Lu, Kang Yao, Man-Di Mu, Chen-Shan Gao, Xin-Yu Weng, Jun-Bo Ge
Background and Aims Survivors of acute coronary syndromes face an elevated risk of recurrent atherosclerosis-related vascular events despite advanced medical treatments. The underlying causes remain unclear. This study aims to investigate whether myocardial infarction (MI)-induced trained immunity in monocytes could sustain proatherogenic traits and expedite atherosclerosis. Methods Apolipoprotein-E
-
Cardiac imaging: focus on safety, optimal delivery, and risk stratification. Eur. Heart J. (IF 39.3) Pub Date : 2023-12-01 Filippo Crea
-
Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry Eur. Heart J. (IF 39.3) Pub Date : 2023-12-01 Jan D Schmitto, Steven Shaw, Jens Garbade, Finn Gustafsson, Michiel Morshuis, Daniel Zimpfer, Jacob Lavee, Yuriy Pya, Michael Berchtold-Herz, AiJia Wang, Carlo Gazzola, Evgenij Potapov, Diyar Saeed
Background and Aims HeartMate 3 (HM3) is a fully magnetically levitated continuous flow left ventricular assist device, which received CE marking in 2015. The ELEVATE Registry was initiated to collect real-world outcomes in patients treated with HM3 post-CE Mark approval. Methods A total of 540 subjects implanted at 26 centres between March 2015 and February 2017 were included in this registry. Of
-
Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways Eur. Heart J. (IF 39.3) Pub Date : 2023-12-01 Yehong Li, Mengze Zhou, Huanqiu Li, Chen Dai, Li Yin, Chunxiao Liu, Yuxin Li, Enming Zhang, Xinli Dong, Hui Ji, Qinghua Hu
Background and Aims Macrophage-derived foam cells play a causal role during the pathogenesis of atherosclerosis. P2Y6 receptor (P2Y6R) highly expressed has been considered as a disease-causing factor in atherogenesis, but the detailed mechanism remains unknown. This study aims to explore P2Y6R in regulation of macrophage foaming, atherogenesis, and its downstream pathways. Furthermore, the present
-
A very rare and unusual complication after a percutaneous patent foramen ovale closure. Eur. Heart J. (IF 39.3) Pub Date : 2023-11-30 Claudiu Ungureanu,Giuseppe Colletti,Jacques Auslender
-
Quality and transparency of clinical evidence for high-risk cardiovascular medical devices: a long way to go. Eur. Heart J. (IF 39.3) Pub Date : 2023-11-30 Piotr Szymański,Rita Redberg
-
A patient-tailored clipping strategy of transcatheter edge-to-edge repair as salvage for cardiogenic shock complicated by mitral valve cleft and bileaflet flails. Eur. Heart J. (IF 39.3) Pub Date : 2023-11-29 Zhi-Nan Lu,Yizhen Yang,Guangyuan Song
-
Martha Gulati: all-round champion of women's heart health. Eur. Heart J. (IF 39.3) Pub Date : 2023-11-29 Judith Ozkan
-
Breaking down barriers to transcatheter aortic-valve implantation in low surgical risk patients. Eur. Heart J. (IF 39.3) Pub Date : 2023-11-29 Rocco Vergallo,Massimo Volpe
-
Shedding the optical coherence tomography light on the treatment of complex coronary bifurcation lesions. Eur. Heart J. (IF 39.3) Pub Date : 2023-11-29 Rocco Vergallo,Leonarda Galiuto
-
Optical coherence tomography to guide percutaneous coronary intervention: is the glass half full or half empty? Eur. Heart J. (IF 39.3) Pub Date : 2023-11-28 Rocco Vergallo,Massimo Volpe
-
Atrial fibrillation first detected after stroke: is timing and detection intensity relevant for stroke risk? Eur. Heart J. (IF 39.3) Pub Date : 2023-11-28 Luciano A Sposato,Gregory Y H Lip,Karl Georg Haeusler
-
-
Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study. Eur. Heart J. (IF 39.3) Pub Date : 2023-11-23 Mariam Anjum,Inger Ariansen,Vidar Hjellvik,Randi Selmer,Lars J Kjerpeseth,Eva Skovlund,Marius Myrstad,Hanne Ellekjær,Ingrid E Christophersen,Arnljot Tveit,Trygve Berge
BACKGROUND AND AIMS The benefit of oral anticoagulant (OAC) therapy in atrial fibrillation (AF) and intermediate stroke risk is debated. In a nationwide Norwegian cohort with a non-sex CHA2DS2-VASc risk score of one, this study aimed to investigate (i) stroke and bleeding risk in AF patients with and without OAC treatment, and (ii) the risk of stroke in non-anticoagulated individuals with and without
-
Anticoagulation for atrial fibrillation in patients with intermediate stroke risk: is the grey zone becoming less grey? Eur. Heart J. (IF 39.3) Pub Date : 2023-11-23 Francis E Marchlinski,Alireza Oraii,Daniele Muser
-
Effectiveness of Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement with High Aortic Valve Calcium Burden Eur. Heart J. (IF 39.3) Pub Date : 2023-11-23 A Gupta, O Koren, V Patel, T Nagasaki, D Patel, K Golwala, T Chakravarty, H Al-Jilaihawi, M Nakamura, R Makkar
Background The use of a cerebral embolic protection device (CEPD) during transcatheter aortic valve replacement (TAVR) has not been shown to be effective in preventing stroke in the PROTECTED-TAVR randomized controlled trial. However, whether CEPD may specifically benefit patients with high aortic valve calcium burden has not been studied. Purpose This study aimed to determine the effectiveness of
-
AfricaSTEMI Live! 2023-a unique learning experience. Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 Habib Gamra,Bernard Gersh,Mohamed Jeilan